Skip to content
OpenCapital
Get started

Viking Therapeutics VKTX Current ratio

Current ratio at other companies

Eli Lilly logo
Eli LillyLLY
1.5×+0.1×
Pfizer logo
PfizerPFE
1.2×0.0×
Amgen logo
AmgenAMGN
1.3×+0.1×
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
3.5×-2.4×
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
18.6×-3.9×
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
22.1×+2.2×

Other financials

Income statement

See full
Revenue-—
Operating income-$164.1M-196%
Net income-$158.3M-247%
EPS (diluted)-$1.37-234%

Balance sheet

See full
Cash & equivalents$118.1M+211%
Total debt$137.0K-87.8%
Total equity$501.9M-40.7%
Total assets$608.2M-29.8%

Cash flow

See full
Operating cash flow-$114.0M-118%

Valuation

See full
Market cap$3.53B+38.7%

Returns & leverage

See full
Return on equity-70%-94.5pp
Debt / equity0×0.0×

Where this comes from

Calculated from Viking Therapeutics’s reported figures.

total current assets/total current liabilities=5.7×

Based on the most recent quarter.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viking Therapeutics's current ratio?
Viking Therapeutics (VKTX) reported current ratio of 5.7× in Q1 2026.
How has Viking Therapeutics's current ratio changed year-over-year?
Viking Therapeutics's current ratio decreased by 87.1% year-over-year, from 44.2× to 5.7×.
What is the long-term trend for Viking Therapeutics's current ratio?
Over 5 years (2020 to 2025), Viking Therapeutics's current ratio has grown at a -15.1% compound annual growth rate (CAGR), from 21.1× to 9.3×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.